@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma
@CarlyHFierce: Teva: Copying GlaxoSmithKline's Advair too tough for success before 2018. ICYMI yesterday | Follow @CarlyHFierce
> As FDA bigwig Dr. Janet Woodcock prepares to retire next year, drugmakers are worrying about who will replace her. Report
> Vivus ($VVUS) said high-risk patients who used its weight loss drug Qsymia were more than 70% less likely to develop diabetes, compared with patients on placebo. Report
> A federal judge rejected two drugmakers' move to keep secret their reports submitted to the federal government to comply with corporate integrity agreements. Report
> The generic drugmaker Lannett closed its public stock offering, which delivered net proceeds of $71.5 million. Report
> The state of Missouri said it would return an anesthetic it planned to use in executions after its manufacturer, Germany's Fresenius Kabi, protested. Report
> Fitch Ratings figures biosimilars uptake will be stronger in the U.S. than it has been in Europe, though acceptance may be slow at first. Report
@FierceMedDev: Medtronic jumps into hemodialysis business through India partnership. ICYMI yesterday | Follow @FierceMedDev
@MarkHFierce: The head of Roche molecular diagnostics spoke to FierceDiagnostics recently about two key future products. More | Follow @MarkHFierce
@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce
> Are medical device companies invited to the biotech IPO party? Editor's corner
> Boston Scientific kicks off drug-eluting stent trial as sales wane. Story
> Quest warns reimbursement pressures, test volume declines will dampen Q3. More
> FDA panel casts doubt on CardioMEMS' heart failure diagnostic. Article
Biotech News
@FierceBiotech: Popular yesterday: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech
@JohnCFierce: Few months after $60M C series and Forest deal, Trevena files for $86M IPO. SEC filing | Press release | Follow @JohnCFierce
@DamianFierce: MacroGenics has up-sized its IPO, now seeking $80M amid biotech blitz. ICYMI yesterday | Follow @DamianFierce
@EmilyMFierce: 3-D printing builds bacterial metropolises. More via ScienceNews | Follow @EmilyMFierce
> Google visionaries ready to invest a fortune in revolutionizing aging process. Article
> Takeda punts $620M antibody licensing pact with Immunomedics. Story
> Gilead scores early PhIII success for idelalisib in chronic lymphocytic leukemia. More
Pharma Manufacturing News
@EricPFierce: Will McKesson and AmerisourceBergen now face off in Europe? Article | Follow @EricPFierce
> Catalent moves on Brazil VMS, softgel market. News
> Vetter putting $100M into its production network. Report
> Teva looks for big savings from procurement, manufacturing. Story
> Feds fight drug imports Maine now allows. More
> BioCentury finds FDA has $270M in GDUFA, PDUFA fees in hand. Item
Vaccines News
> WHO prequalification moves China into global vaccine arena. Item
> Novartis opening vaccine R&D lab in North Carolina. Report
> Takeda's norovirus vaccine misses endpoint in early-phase trial. Story
> GSK targets 2015 launch for malaria vaccine. Article
> HIV trial follow-up quashes fears of infection risk. More
And Finally... Can peanut butter help diagnose Alzheimer's disease? Report